Gemtesa is a brand-name medication available in a 75mg tablet formulation [1]. It is prescribed to treat adults with overactive bladder (OAB) [1].
What is Gemtesa used for?
Gemtesa is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency in adult patients [1].
How does Gemtesa work?
Gemtesa contains the active ingredient vibegron, which is a beta-3 adrenergic agonist [1]. Vibegron relaxes the detrusor smooth muscle, which is the muscle in the bladder wall, allowing the bladder to hold more urine [1]. This can help reduce the symptoms of OAB [1].
What are the different strengths of Gemtesa?
Gemtesa is available in a 75mg tablet [1].
How should Gemtesa be taken?
Gemtesa 75mg tablets are taken orally, once a day, with or without food [1].
What are the potential side effects of Gemtesa?
Common side effects of Gemtesa may include headache, nasopharyngitis (common cold symptoms), diarrhea, nausea, and upper respiratory tract infection [1].
When does Gemtesa's patent expire?
DrugPatentWatch.com provides information on drug patent expirations. Specific patent expiration dates for Gemtesa would need to be checked on their platform or through other pharmaceutical patent databases [2]. Patent exclusivity can be affected by various factors, including patent challenges and regulatory decisions [2].